Department of Pharmaceutical Sciences and Drug Research, Punjabi University, Patiala, India.
Laboratory of Molecular Medicine, Department of Human Genetics and Molecular Medicine, Central University of Punjab, Bathinda, India.
Int J Biol Macromol. 2021 May 1;178:29-40. doi: 10.1016/j.ijbiomac.2021.02.132. Epub 2021 Feb 22.
Sinapic acid (SA), a widely prevalent hydroxycinnamic acid, possess numerous biological activities owing to its antioxidant property. The present study was aimed to prepare colon targeted polysaccharidic/polymeric ester prodrug of SA (a microbially triggered system) using Leucaena leucocephala galactomannan (LLG) as a polysaccharidic carrier. The polymeric conjugates of SA-LLG were found to exhibit an increase in % yield and DS with increase in amount of SA and volume of thionyl chloride. The degree of depolymerization of SA-LLG prodrug batches were evaluated using optimized concentration of galactomannase. The SA-LLG prodrug was characterized employing UV and FTIR spectroscopy, H NMR and XRD. In vitro release study of the optimized prodrug batch (SL10) suggested stable nature of SA-LLG conjugate under acidic (pH 1.2) and alkaline conditions (pH 6.8). The treatment of prodrug with galactomannase (15 mg/mL) followed by esterase (10 U/mL) enzyme released approximately 81% of SA after 24 h. The cell viability results revealed that free SA and SA-LLG were found to have similar antiproliferative potential against human colon cancer cell lines (HCT-116 cells). Our investigation revealed that polysaccharidic prodrug, SA-LLG, has the potential for colon targeting of SA and thus can be employed for the treatment of Inflammatory Bowel Diseases (IBDs).
水杨酸(SA)是一种广泛存在的羟基肉桂酸,由于其抗氧化性能,具有许多生物活性。本研究旨在使用银合欢半乳甘露聚糖(LLG)作为多糖载体,制备 SA 的结肠靶向多糖/聚合物酯前药(一种微生物触发系统)。结果发现,随着 SA 用量和氯化亚砜体积的增加,SA-LLG 聚合物缀合物的产率和取代度(DS)呈增加趋势。使用优化浓度的半乳甘露聚糖酶评估 SA-LLG 前药批次的解聚程度。采用紫外和傅里叶变换红外光谱、氢核磁和 X 射线衍射对 SA-LLG 前药进行了表征。优化前药批次(SL10)的体外释放研究表明,SA-LLG 缀合物在酸性(pH 1.2)和碱性条件(pH 6.8)下具有稳定的性质。用半乳甘露聚糖酶(15 mg/mL)处理前药,然后用酯酶(10 U/mL)酶处理,大约 24 小时后释放出约 81%的 SA。细胞活力结果表明,游离 SA 和 SA-LLG 对人结肠癌细胞系(HCT-116 细胞)具有相似的抗增殖潜力。我们的研究表明,多糖前药 SA-LLG 具有 SA 的结肠靶向潜力,因此可用于治疗炎症性肠病(IBD)。